Decreased excretion of urine glycosaminoglycans as marker in renal amyloidosis

Nephrology Dialysis Transplantation

Volumn 12, Issue 6, 1997, Pages 1161-1166

  Tencer, Jan ^a   Torffvit, Ole ^a   Grubb, Anders ^a   Björnsson, Sven ^a,b   Thysell, Hans ^a   Rippe, Bengt ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b CENTRAL HOSPITAL   (Sweden)

Author keywords

AA amyloidosis; AL amyloidosis; Disease; Glomerular; Glycosaminoglycans

Indexed keywords

ACUTE PHASE PROTEIN; ALBUMIN; AMYLOID; CREATININE; GLYCOSAMINOGLYCAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE URINE LEVEL; HUMAN; KIDNEY AMYLOIDOSIS; KIDNEY FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINURIA; AMYLOIDOSIS; BIOLOGICAL MARKERS; CREATININE; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MIDDLE AGED;

EID: 0030982032     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.6.1161     Document Type: Article

References (41)

1. Adler SG, Cohen AH, Glassock RJ. Secondary glomerular diseases. In: Brenner BM. ed. The Kidney. WB Saunders Company, Philadelphia London Toronto Montreal Sydney Tokyo: 1995: 1540-1541
2. Bohlc A, Wehrmann M, Eissele R et al. The long-term prognosis of AA and AL renal amyloidosis and the pathogenesis of chronicrenal failure in renal amyloidosis. Path Res Pract 1993; 189: 316-331
3. Benditt EP, Eriksen N. Chemical classes of amyloid substance. Am J Pathol 1971; 65: 231-249
4. Löfberg H, Grubb A, Thysell H et al. The prevalence of renal amyloidosis of the AA-type in a series of 1,158 consecutive autopsies. Acta Path Microbiol Immunol Scand 1987; 95: 297-302
5. Berglund K, Thysell H, Keller C. Results, principles and pitfalls in management of renal AA-amyloidosis; a 10-21 year follow-up of 16 patients with rheumatic disease treated with alkylating cytostatics. J Rheumatol 1993; 20: 2051-2057
6. Hawkins PN. Amyloidosis. Blood-Rev 1988; 2: 270-280
7. Hurst RE. Structure, function, and pathology of proteoglycans and glycosaminoglycans in the urinary tract. World J Urol 1994; 12: 3-10
8. Höök M, Kjellen L, Johansson S, Robinson J. Cell-surface glycosaminoglycans. Annu Rev Biochem 1984; 53: 847-869
9. Guder WG, Jakubowski Z, Angielski S. Clinical biochemistry in renal diseases. Basic knowledge and diagnostic approaches. Eur J Clin Chem Clin Biochem 1992; 30: 617-625
10. Mitsuhashi H, Tsukada Y, Ono K, Yano S, Naruse T. Urine glycosaminoglycans and heparan sulfate excretions in adult patients with glomerular diseases. Clin Nephrol 1993; 39: 231-237
11. 125I-bovine serum albumin. Lab Invest 1982; 47: 177-184
12. Cotran RS, Rennke HG. Anionic sites and the mechanisms of proteinuria. N Engl J Med 1983; 309: 1050-1052
13. Timple R. Structure and biological activity of basement membrane proteins. Eur J Biochem 1989; 180: 487-502
14. Kanvar YS, Farquhar MG. Presence of heparan sulfate in the glomerular basement membrane. Proc Natl Acad Sci USA 1979; 76: 1303-1307
15. Grogel GC, Stevenson J, Hovingh P, Linker A, Border WA. Changes in heparan sulfate correlate with increased glomerular permeability. Kidney Int 1988; 33: 517-523
16. Löfberg H, Thyseli H, Westman K et al. Demonstration and classification of amyloidosis in needle biopsies of the kidneys, with special reference to amyloidosis of the AA-type. Acta Path Microbiol Immunol Scand 1987; 95: 357-363
17. Price CP, Whicher J. Light-scattering immunoassay of specific proteins: a review. Ann Clin Biochem 1983; 20: 1-14
18. Svendsen PJ, Blirup-Jensen S. Determination of human plasma proteins by turbidimetry and nephelometry. DAKO A/S, Copenhagen, 1991; 1-35
19. Tencer J, Thysell H, Grubb A. Stability of albumin, protein HC, immunoglobulin G, κ- and λ-chain immunoreactivity, orosomucoid and α1-antitrypsin in urine stored at various conditions. Scand J Clin Lab Invest 1994; 54: 199-206
20. Tencer J, Thysell H, Westman K, Rippe B. Elevated plasma levels of acute phase proteins in proliferative glomerulonephritis, membranous nephropathy and IgA nephropathy. Scand J Urol Nephrol 1995; 29: 5-9
21. Shaw AB, Risdon P, Lewis-Jackson JD. Protein creatinine index and Albustix in assessment of proteinuria. Br Med J 1983; 287: 929-932
22. Dyson EH, Will EJ, Davison AM, O'Malley AH, Shepard HT, Jones RG. Use of the urinary protein creatinine index to assess proteinuria in renal transplant patients. Nephrol Dial Transplant 1992; 7: 450-452
23. Farndale RW, Sayers CA, Barrett AJ. A direct spectrophotometric microassay for sulfated glycosaminoglycans in cartilage cultures. Connective Tissue Res 1982; 9: 247-248
24. Klompmakers AA, Hendriks T. A spectrophotometric microassay for sulphated glycosaminoglycans using a laser densitometer. Analyt Biochem 1986; 153: 80-84
25. Ratcliffe A, Doherty M, Maini RN, Hardigham TE. Increased concentration of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann Rheum Dis 1988; 47: 826-832
26. de Jong JGN, Wevers RA, Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin Chem 1992; 38: 803-807
27. Björnsson S. Simultaneous preparation and quantitation of proteoglycans by precipitation with alcian blue. Anal Biochem 1993; 210: 282-291
28. Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N Eng J Med 1983; 309: 1543-1546
29. Levin M, Smith C, Walter MDS, Gascoine P, Barrat TM. Steroid responsive nephrotic syndrome, a generalized disorder of membrane negative charge. Lancet 1985; II: 239-242
30. Bernard AM, Ouled A, Roels H, Lauwerys R, Vandeleene B, Lambert A. Lack of relationship between urinary glycosaminoglycans and indices of tubular or glomerular renal damage. Urinary GAG are an unreliable nephrotoxicity index. Nephron 1988; 48: 82-83
31. van den Born J, van den Heuvel LP, Bakker MAH et al. Distribution of GBM heparan sulfate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1992; 43: 454-463
32. Mahan JD, Sisson-Ross S, Vernier RL. Glomerular basement membrane anionic charge site changes in aminonucleoside nephrosis. Am J Pathol 1986; 125: 393-401
33. Blau EB, Haas JE. Glomerular sialic acid and proteinuria in human renal disease. Lab Invest 1973; 38: 477-481
34. Okada K, Kawakami K, Miyao M, Oite T. Ultrastructural alterations of glomerular anionic sites in idiopathic membranous glomerulonephritis. Clin Nephrol 1986; 26: 7-14
35. Tomino Y, Yagame M, Eguchi K et al. Detection of anionic sites and immunoglobulin A deposits in the glomerular capillary walls from patients with IgA nephropathy. J clin Lab Anal 1989; 3: 101-107
36. Okada K, Kawakami K, Yano I et al. Ultrastructural alterations of glomerular anionic sites in IgA nephropathy. Clin Nephrol 1989; 31: 96-102
37. Vernier RL, Steffes MW, Sisson RS, Mauer SM. Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney Int 1992; 41: 1070-1080
38. Norling B, Westermark GT, Westermark P. Immunohistochemical identification of heparan sulphate proteoglycan in secondary systemic amyloidosis. Clin Exp Immunol 1988; 73: 333-337
39. Snow AD, Willmer J, Kisilewsky R. A close ultrastructural relationship between sulfated proteoglycans and AA amyloid fibrils. Lab Invest 1987; 57: 687-698
40. Leveugle B, Scanameo A, Ding W, Fillit H. Binding of heparan sulfate glycosaminoglycan to β-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 1994; 5: 1389-1392
41. Kéry V, Orlovska M, Stancikova M, Risko M. Zlnay D. Urinary glycosaminoglycan excretion in rheumatic diseases. Clin Chem 1992; 38: 841-846